Context
Tendon-injury claims need to be read alongside rehab, imaging, loading progression, and follow-up care.
Compare BPC-157, TB-500, and GHK-Cu recovery claims, including the human-evidence gap and the product-quality questions that make this space confusing.
Peptides compared
BPC-157
A heavily promoted repair and gut peptide where human evidence is still limited to a few narrow sources and FDA-flagged compounding concerns.
TB-500
A recovery-focused peptide name where the first question is whether the source means the TB-500 fragment, full-length thymosin beta-4, or a market vial.
GHK-Cu
A copper-binding tripeptide with route-specific topical skin and wound evidence, plus much weaker systemic, hair, blend, and injectable claim areas.
Sources
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing 2025.
PMID:40789979 Accessed 2026-06-08.
Narrative review that helps explain the recovery discussion but does not prove broad clinical recovery efficacy.
- 4.
PubMed. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper 1994.
PMID:17147644 Accessed 2026-06-08.
Topical diabetic-ulcer source; not evidence for injectable or systemic claims.